Effects of oral pregabalin and aprepitant on pain and central sensitization in the electrical hyperalgesia model in human volunteers

British Journal of Anaesthesia

Volumn 98, Issue 2, 2007, Pages 246-254

  Chizh, Boris A ^a   Gohring M ^b   Troster A ^b   Quartey, G K ^c   Schmelz, M ^d   Koppert, W ^b  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c GLAXOSMITHKLINE   (United Kingdom)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Analgesics, non opioid; Analgesics, non steroidal; Anticonvulsants; Pain, experimental; Pain, neuropathic

Indexed keywords

APREPITANT; PARECOXIB; PLACEBO; PREGABALIN; SODIUM CHLORIDE; 4 AMINOBUTYRIC ACID; ANALGESIC AGENT; DRUG DERIVATIVE; ISOXAZOLE DERIVATIVE; MORPHOLINE DERIVATIVE; PROSTAGLANDIN SYNTHASE INHIBITOR;

ABNORMAL DREAMING; ADULT; AGED; ALLODYNIA; ANALGESIA; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; EXPERIMENTAL MODEL; FATIGUE; FEMALE; GERMANY; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPERALGESIA; MALE; MEDICAL RESEARCH; MUSCLE WEAKNESS; NOCICEPTION; NORMAL HUMAN; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TASTE DISORDER; TONGUE DISEASE; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; VOLUNTEER; XEROSTOMIA; CONTROLLED CLINICAL TRIAL; DRUG COMBINATION; ELECTROSTIMULATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PAIN ASSESSMENT; PATHOLOGY;

ADMINISTRATION, ORAL; ADULT; ANALGESICS; CROSS-OVER STUDIES; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ELECTRIC STIMULATION; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; HYPERALGESIA; ISOXAZOLES; MALE; MIDDLE AGED; MORPHOLINES; PAIN MEASUREMENT; TREATMENT OUTCOME;

EID: 33847764570     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/ael344     Document Type: Article

References (32)

1. Wallace MS. Diagnosis and treatment of neuropathic pain. Curr Opin Anaesthesiol 2005; 18: 548-54
2. Dworkin RH, Backonja M, Rowbotham MC, Allen RR, Argoff CR, Bennett GJ, Bushnell MC, Farrar JT, Galer BS, Haythornthwaite JA, Hewitt DJ, Loeser JD, Max MB, Saltarelli M, Schmader KE, Stein C, Thompson D, Turk DC, Wallace MS, Watkins LR, Weinstein SM. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003; 60: 1524-34
3. Hill R. NKI (substance P) recepctor antagonists-why are they not analgesic in humans? Trends Pharmacol Sci 2000; 21: 244-6
4. Millan MJ. The induction of pain: An integrative review. Prog Neurobiol 1999; 57: 1-164
5. Woolf CJ, Mannion RJ. Neuropathic pain: Aetiology, symptoms, mechanisms, and management. Lancet 1999; 353: 1959-64
6. Jensen TS, Baron R. Translation of symptoms and signs into mechanisms in neuropathic pain. Pain 2003; 102: 1-8
7. Zimmermann M. Pathobiology of neuropathic pain. Eur J Pharmacol 2001; 429: 23-37
8. Koppert W, Dern SK, Sittl R, Albrecht S, Schuttler J, Schmelz M. A new model of electrically evoked pain and hyperalgesia in human skin: The effects of intravenous alfentanil, S(+)-ketamine, and lidocaine. Anesthesiology 2001; 95: 395-402
9. Klede M, Handwerker HO, Schmelz M. Central origin of secondary mechanical hyperalgesia. J Neurophysiol 2003; 90: 353-9
10. Chizh BA, Dusch M, Puthawala M, Schmelz M, Cookson LM, Martina R, Brown J, Koppert W. The effect of intravenous infusion of adenosine on electrically-evoked hyperalgesia in a healthy volunteer model of central sensitization. Anesth Analg 2004; 99: 816-22
11. Koppert W, Ihmsen H, Korber N, Wehrfritz A, Sittl R, Schmelz M, Schuttler J. Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model. Pain 2005; 118: 15-22
12. Koppert W, Wehrfritz A, Korber N, Sittl R, Albrecht S, Schuttler J, Schmelz M. The cyclooxygenase isozyme inhibitors parecoxib and paracetamol reduce central hyperalgesia in humans. Pain 2004; 108: 148-53
13. Koppert W, Goehring M, Troester A, Quartey GK, Schmelz M, Chizh BA. Validation of the electrical hyperalgesia model in human volunteers: Effects of oral pregabalin and the NKI antagonist aprepitant. Eur J Anaesthesiol 2006; 23 (Suppl. 37): PA4
14. Dworkin RH, Corbin AE, Young JP Jr, Sharma U, LaMoreaux L, Bockbrader H, Garofalo EA, Poole RM. Pregabalin for the treatment of postherpetic neuralgia: A randomized, placebo-controlled trial. Neurology 2003; 60: 1274-83
15. Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: A double-blind, placebo-controlled trial. Pain 2004; 110: 628-38
16. Block GA, Rue D, Panebianco D, Reines SA. The L-754 OPsg: The substance P receptor antagonist L-754,030 (MK-0869) is ineffective in the treatment of postherpetic neuralgia. Neurology 1998; 50: pA225-6
17. Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, Taylor A, Carides AD, Evans JK, Horgan KJ. Establishing the dose of the oral NKI antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 2003; 97: 2290-300
18. Bergstrom M, Hargreaves RJ, Burns HD, Goldberg MR, Sciberras D, Reines SA, Petty KJ, Ogren M, Antoni G, Langstrom B. Human positron emission tomography studies of brain neurokinin I receptor occupancy by aprepitant. Biological Psychiatry 2004; 55: 1007-12
19. Rolke R, Magerl W, Campbell KA, Schalber C, Caspari S, Birklein F, Treede RD. Quantitative sensory testing. a comprehensive protocol for clinical trials. Eur J Pain 2006; 10: 77-88
20. Gottrup H, Juhl G, Kristensen AD, Lai R, Chizh BA, Brown J, Bach FW, Jensen TS. Chronic oral gabapentin reduces elements of central sensitization in human experimental hyperalgesia. Anesthesiology 2004; 101: 1400-8
21. Koppert W, Sittl R, Scheuber K, Alsheimer M, Schmelz M, Schuttler J. Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans. Anesthesiology 2003; 99: 152-9
22. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain. evidence from randomized, placebo-controlled clinical trials. Clin Ther 2003; 25: 81-104
23. Dirks J, Petersen KL, Rowbotham MC. Gabapentin suppresses cutaneous hyperalgesia following heat-capsaicin sensitization. Anesthesiology 2002; 97: 102-7
24. Boyce S, Hill RG. Discrepant results from preclinical and clinical studies on the potential of substance P-receptor antagonist compounds as analgesics. In: Devor M, Rowbotham MC, Wiesenfeld-Hallin Z, eds. Proceedings of the 9th World Congress on Pain, Volume 16, Seattle: IASP Press, 2000; 313-24
25. Goldstein DJ, Wang O, Gitter BD, Iyengar S. Dose-response study of the analgesic effect of lanepitant in patients with painful diabetic neuropathy. Clin Neuropharmacol 2001; 24: 16-22
26. Goldstein DJ, Wang O, Todd LE, Gitter BD, DeBrota DJ, Iyengar S. Study of the analgesic effect of lanepitant in patients with osteoarthritis pain. Clin Pharmacol Ther 2000; 67: 419-26
27. Rupniak NM, Kramer MS. Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NKI) antagonists. Trends Pharmacol Sci 1999; 20: 485-90
28. Dando TM, Perry CM. Aprepitant: A review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 2004; 64: 777-94
29. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ. The oral neurokinin-I antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003; 21: 4112-9
30. Gilron I, Max MB. Combination pharmacotherapy for neuropathic pain: current evidence and future directions. Expert Rev Neurother 2005; 5: 823-30
31. Desmeules J, Rollason V, Piguet V, Dayer P. Clinical pharmacology and rationale of analgesic combinations. Eur J Anaesthesiol Suppl 2003; 28: 7-11
32. Gilron I, Orr E. Tu D, O'Neill PJ, Zamora JE, Bell AC. A placebo-controlled randomized clinical trial of perioperative administration of gabapentin, rofecoxib and their combination for spontaneous and movement-evoked pain after abdominal hysterectomy. Pain 2005; 113: 191-200